Slides: Current First-line Treatment Options for Metastatic Pancreatic Cancer

Download this concise slideset for expert perspectives on first-line systemic therapy considerations for patients with advanced pancreatic cancer.
Andrew H. Ko, MD
Program Director
Format: Microsoft PowerPoint (.ppt)
File Size: 561 KB
Released: February 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Ipsen Biopharmaceuticals, Inc.

Related Content

Video from Clinical Care Options (CCO) featuring expert insights into the optimal current treatment of pancreatic cancer

Andrew H. Ko, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 15, 2021 Expired: April 14, 2022

Prof. Dr. Arndt Hartmann, Prof. Dr. Arndt Hartmann has disclosed that he has received consulting fees from Agilent, AstraZeneca, Bristol-Myers Squibb, Diaceutics, Janssen, MSD, Pfizer, and Roche. Released: April 9, 2021

CCO downloadable PDF: Targeting FGFR in urothelial cancer and other malignancies

Alison Birtle, MD, FRCP, FRCR person default Ignacio Duran, MD, PhD Released: April 1, 2021

Online tool from Clinical Care Options (CCO) providing therapeutic recommendations from 5 HCC experts for your specific patients

Richard S. Finn, MD
Program Director
Thomas A. Abrams, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Andrew X. Zhu, MD, PhD, FACP
Released: March 31, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue